Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.55 |
| ▸ | CALML3 | P27482 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SDHA | P31040 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 7/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8489164 | 1.00 | MAOA (0.55) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL13298924 | 0.93 | MAOA (0.61) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL8311890 | 0.90 | MAOA (0.59) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL9550276 | 0.88 | MAOA (0.57) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL9550299 | 0.88 | MAOA (0.57) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL9550262 | 0.88 | MAOA (0.57) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL10423881 | 0.88 | ABCB11 (0.51) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL21324902 | 0.88 | ABCB11 (0.51) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL10425344 | 0.87 | MAOA (0.54) | MAOAMAOBCALML3LMNAPTGS1 | |
| SCHEMBL9550268 | 0.87 | ABCB11 (0.56) | MAOAMAOBCALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807623-B2 | Nucleic acid-binding photoprobes and uses thereof | ARRAKIS THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807623-B2 | Nucleic acid-binding photoprobes and uses thereof | ARRAKIS THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230312520-A1 | NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312520-A1 | NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20190270723-A1 | NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF | ARRAKIS THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| WO-1999033839-A1 | CEPHEM DERIVATIVES AND A METHOD FOR PRODUCING THE COMPOUNDS AND AN ANTIBACTERIAL COMPOSITION CONTAINING THE COMPOUNDS | CHEIL JEDANG CORPORATION (KR) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270723-A1 | NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF | NSUN3, NSUN2, TARBP1 | MAOA 2886/4885MAOB 1343/4885CALML3 2458/4885 |
| US-20230312520-A1 | NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF | NSUN3, NSUN2, TARBP1 | MAOA 2886/4885MAOB 1343/4885CALML3 2458/4885 |
| US-11807623-B2 | Nucleic acid-binding photoprobes and uses thereof | NSUN3, NSUN2, TARBP1 | MAOA 2886/4885MAOB 1343/4885CALML3 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.